Name: FELIPE TONON FIRMINO
Publication date: 26/09/2023
Examining board:
Name |
Role |
|---|---|
| NAZARE SOUZA BISSOLI | Advisor |
Summary: GLP-1 receptor (glucagon-like peptide-1) agonists have beneficial cardiovascular effects through mechanisms other than glycemic control. However, the renal effects of the antidiabetic drug Liraglutide in a model of hypertension associated with ovarian hormone deficiency have not yet been investigated. SHR female rats (8 weeks old) were used. Ovariectomy or sham surgery were performed. The rats were separated into: saline SHAM (S); SHAM + Liraglutide (0.06 mg/kg/day - SLL); SHAM + Liraglutide (0.6 mg/kg/day - SLH); saline OVX (O); OVX + Liraglutide (0.06 mg/kg/day - OLL); OVX + Liraglutide (0.6 mg/kg/day - OLH) groups and treated for 30 days. Systolic blood pressure (SBP) was verified using the tail plethysmography method. Fasting blood glucose was measured using a glucometer. The parameters of urinary volume excreted in the 24-hour period were monitored with the aid of a metabolic cage. In renal tissue, nitrite (NO2-) and nitrate (NO3-) analyzes were performed using the Griess method and oxidative stress was assessed by analyzing the content of advanced protein oxidation products (AOPP). Renal collagen deposition was determined using Picrosirius red staining. Lipase, creatinine and plasma urea were analyzed by the enzymatic kinetic method and urinary sodium by selective electrode. Liraglutide reduced body weight gain in the S groups but was not able to prevent the increase in O. Liraglutide only at high dose increased urinary excretion in both S and O. Independent of dose, liraglutide increased nitrate and reduced nitrite in the presence of OH, in O these alterations were not observed. AOPP were reduced in SLL and OLH. Urea and sodium increased in SLL and OLL and creatinine and urea in OLH. Effects were independent of blood pressure and glycemic control in liraglutide-treated animals. Liraglutide appears to have a differentiated action on the kidney of hypertensive females, depending on dose and hormonal status. Therefore, the use of this drug in
relation to the dose and the clinical situation of the individual involved in the treatment must be considered.
